Modus Therapeutics Holding AB

Modus is a Swedish biotechnology company that is developing its proprietary polysaccharide sevuparin as a potential treatment for several major healthcare needs including sepsis/septic shock and other disorders with severe systemic inflammation such as severe malaria, as well as states of anemia, related to chronic inflammation such as kidney disease. There is a great need for new treatments that can effectively treat these conditions. Modus’ ambition is to create a paradigm shift in the care of these diseases, where sevuparin could provide therapeutic benefits.

To subscribe for one (1) new share at the subscription price of SEK 0.35 per share one (1) warrant TO 2 is needed. For subscription with warrants on a VP-account, the below subscription form can be used. If your warrants is in a nominee account at a bank you need to subscibe through the bank where your warrants is located.